You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Oligonucleotide Enzyme Surrogate (OnES)

    SBC: Accacia International LLC            Topic: CBD08108

    Historically organophosphorus compounds such as insecticides and nerve agents have been susceptible to decomposition by proteinaceous enzymes. Organophosphate hydrolases (OPH) represent a practical method to deactivate such compounds peripherally and on surfaces. However, when such organophosphates are ingested, the use of proteinaceous enzymes such as OPH can be problematic because of their tende ...

    SBIR Phase I 2008 Department of DefenseOffice for Chemical and Biological Defense
  2. Profiling ER, PR, EGFR and HER2 in Breast Cancer Using Multiplex Tissue Immusta

    SBC: 20 20 Genesystems Inc            Topic: N/A

    DESCRIPTION (provided by applicant): We propose to develop a novel method and kit for profiling the expression and activation of signal transduction proteins in breast tumors. The goal is to create new companion diagnostics to better select patients like ly to respond to targeted therapies, including Herceptin. and novel tyrosine kinase inhibitors. 20/20 will utilize its proprietary Layered Expr ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  3. Inhaled nisin as an emergency intervention against antibiotic sensitive or resist

    SBC: AFG BIOSOLUTIONS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The deliberate release of Bacillus anthracis spores remains an imminent threat both in terms of bioterrorism and biowarfare. Individuals who inhale these spores are at extreme risk of infection and death from anthrax. C urrent prophylaxis and therapy in the event of B. anthracis spore inhalation fall into two categories. Vaccination to protect against future ex ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  4. Multiplex Lyme Disease Diagnostic

    SBC: AGAVE BIOSYSTEMS INC.            Topic: N/A

    DESCRIPTION (provided by investigator): Lyme disease, caused by the gram-negative spirochete Borrelia burgdorferi and transmitted by Ixodid tick species, is the leading vector-borne infectious disease in the United States, with a steady rise in the number of cases reported each year. The most common Lyme disease symptom, the classic bull's-eye rash (erythema migrans or EM rash) in endemic areas, ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  5. Ribozymes for In Vivo Degradation of G-Nerve Agents

    SBC: AGAVE BIOSYSTEMS INC.            Topic: CBD08108

    Given the possibility to administer prophylactic doses of protein bioscavengers inactivating OP nerve agents before they reach their acetylcholinesterase target, much attention has been given to proteins such as human butyrylcholinesterase and paraoxonase I. As small nucleic acid catalysts can exhibit triphosphoesterase activities, the identification of new molecules active against nerve agents w ...

    SBIR Phase I 2008 Department of DefenseOffice for Chemical and Biological Defense
  6. Collective Protection for Military Working Dogs

    SBC: AGAVE BIOSYSTEMS INC.            Topic: CBD08103

    Shelter enclosures for military working dogs in the event of a CB attack is a technology gap identified by the Joint Requirements Office. Important parameters to consider in the design of protective enclosures include low weight and size to minimize transport requirements; rapid setup; and accommodation of canine physiological and psychological comfort needs. The overall operational weight of th ...

    SBIR Phase I 2008 Department of DefenseOffice for Chemical and Biological Defense
  7. Lactoferrin Enhances Growth and Reduces Nosocomial Infection in Preterm Infants

    SBC: AGENNIX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): This project aims to develop talactoferrin (TLF, recombinant human lactoferrin) as a therapeutic agent to treat prematurely born neonates. The treatment will be given orally shortly after birth to prevent nosocomial inf ections (NIs) due to abnormal bacterial invasion of neonatal intestinal epithelia and consequently to limit systemic bacteremia and necrotizing ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  8. Treatment of Sepsis with Talactoferrin

    SBC: AGENNIX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Severe sepsis is a major cause of morbidity and mortality throughout the world. It is the leading cause of death in non-coronary intensive care units (ICUs) in the United States, with more than 750,000 cases occurring every year. This means that in the United States, more than 500 patients die from severe sepsis every day, with 28% to 50% of the patients succum ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  9. SUBCUTANEOUS MONITOR/ALARM FOR CARDIAC ARREST

    SBC: AJ MEDICAL DEVICES, INC.            Topic: N/A

    It is estimated that 220,000 people suffer cardiac arrest each year in the US, of whom only 10,000 survive to hospital discharge. The number of survivors could increase 10-fold if paramedical attention and/or defibrillation were available within a few min

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  10. Add-on module for ONCAD for diagnosing infiltrating lobular carcinoma

    SBC: Alan Penn & Associates Inc            Topic: N/A

    DESCRIPTION (provided by applicant): The specific aim of this study is to develop an add-on module for the ONCAD breast MRI CAD system that will provide radiologists with additional assistance when they have suspicion of the presence of infiltrating lobula r carcinoma (ILC). The proposed research will investigate the possibility of developing, training and evaluating an ILC- specific algorithm tha ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government